Maximus (NYSE:MMS) Updates FY 2026 Earnings Guidance

Maximus (NYSE:MMS) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 8.250-8.550 for the period, compared to the consensus earnings per share estimate of 8.360. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.3 billion.

Maximus Price Performance

Shares of MMS stock opened at $64.08 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.34. The company has a market capitalization of $3.50 billion, a P/E ratio of 9.75 and a beta of 0.60. The company’s 50-day simple moving average is $68.95 and its two-hundred day simple moving average is $80.14. Maximus has a one year low of $60.75 and a one year high of $100.00.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, February 5th. The health services provider reported $1.85 EPS for the quarter, topping analysts’ consensus estimates of $1.84 by $0.01. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.61 EPS. As a group, equities analysts anticipate that Maximus will post 8.46 EPS for the current year.

Maximus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be issued a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, May 15th. Maximus’s dividend payout ratio (DPR) is presently 20.09%.

Analyst Ratings Changes

Several equities analysts recently issued reports on MMS shares. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen lowered shares of Maximus from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Weiss Ratings lowered shares of Maximus from a “buy (b)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Two analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold”.

Insider Activity at Maximus

In related news, Director Jan Madsen sold 742 shares of Maximus stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $72.25, for a total transaction of $53,609.50. Following the transaction, the director directly owned 20,795 shares of the company’s stock, valued at $1,502,438.75. This trade represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO David Mutryn acquired 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were acquired at an average cost of $75.62 per share, for a total transaction of $75,620.00. Following the completion of the acquisition, the chief financial officer owned 40,037 shares of the company’s stock, valued at $3,027,597.94. This trade represents a 2.56% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Maximus

Several institutional investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its stake in Maximus by 13.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,268 shares of the health services provider’s stock valued at $109,000 after acquiring an additional 150 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Maximus by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock valued at $2,351,000 after acquiring an additional 221 shares in the last quarter. Larson Financial Group LLC boosted its stake in Maximus by 13.8% in the third quarter. Larson Financial Group LLC now owns 1,869 shares of the health services provider’s stock valued at $171,000 after acquiring an additional 227 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Maximus by 225.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 439 shares of the health services provider’s stock valued at $38,000 after acquiring an additional 304 shares in the last quarter. Finally, National Bank of Canada FI boosted its stake in Maximus by 38.9% in the third quarter. National Bank of Canada FI now owns 1,118 shares of the health services provider’s stock valued at $102,000 after acquiring an additional 313 shares in the last quarter. 97.21% of the stock is currently owned by institutional investors and hedge funds.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.